导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.41% | 2307/4773 |
| 近一周 | -2.94% | 3413/5462 |
| 近一月 | -7.58% | 3880/5421 |
| 近一季 | -13.54% | 4030/5209 |
| 近半年 | -2.00% | 1746/4920 |
| 近一年 | 1.93% | 2231/4366 |
| 近两年 | 62.78% | 1128/2954 |
| 近三年 | 34.84% | 873/2253 |
| 成立以来 | 128.46% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.74% 2453/4961 |
21.14% 1187/5312 |
- - |
- - |
| 2025 | 26.55% 1622/4813 |
-0.39% 2227/3635 |
-0.50% 2944/4076 |
30.30% 1187/4524 |
-2.01% 3059/4813 |
| 2024 | 15.36% 939/3463 |
0.41% 982/2808 |
-3.18% 1310/3014 |
20.17% 748/3129 |
-1.26% 1636/3463 |
| 2023 | -14.63% 1612/2656 |
4.28% 996/2280 |
-5.97% 1570/2385 |
-6.74% 1499/2515 |
-6.64% 1857/2655 |
| 2022 | -23.75% 1166/2207 |
-18.12% 1302/1919 |
9.14% 297/2016 |
-16.33% 1442/2113 |
1.98% 1069/2208 |
| 2021 | 2.43% 632/1822 |
-3.97% 838/1255 |
11.25% 386/1330 |
-7.10% 1022/1466 |
3.19% 464/1822 |
| 2020 | 50.35% 168/1250 |
-5.39% 414/1028 |
21.80% 224/1067 |
10.46% 552/1164 |
18.13% 101/1184 |
| 2019 | 56.75% 64/1092 |
37.76% 71/754 |
-2.77% 364/804 |
4.88% 176/850 |
11.58% 55/918 |
| 2018 | -31.70% 504/834 |
- - |
- - |
- - |
-13.67% 546/691 |
| 2017 | 31.17% 50/714 |
- - |
- - |
- - |
- - |
| 2016 | -12.06% 299/605 |
- - |
- - |
- - |
- - |
| 2015 | 19.04% 122/575 |
- - |
- - |
- - |
- - |
| 2014 | 30.95% 159/237 |
- - |
- - |
- - |
- - |
| 2013 | -2.21% 71/186 |
- - |
- - |
- - |
- - |
| 2012 | 0.74% 110/140 |
- - |
- - |
- - |
- - |
| 2011 | -29.69% 89/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 招商深证100指数A VS. 长安沪深300非周期A(740101) |